Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Alpa Laboratories Ltd (ALPA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532878 NSE: ALPA Pharmaceuticals & Drugs | Small Cap | Alpa Laboratories Share Price
₹58.27 0.30 (0.52%)
As on 14-Oct'26 16:59
Alpa Laboratories Ltd (ALPA)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532878 NSE: ALPA Pharmaceuticals & Drugs | Small Cap | Alpa Laboratories Share Price
₹58.27 0.30 (0.52%)
As on 14-Oct'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹121 Cr.
Current Price
₹58.3
52-Week Low / High
₹46 / 100
TTM EPS
₹2.1
TTM Sales
₹111 Cr.
Book Value per Share
₹89
P/E Ratio
27.68
Higher than its 5-year historical median
Industry PE
52.6
Price to Book (P/B)
0.65
Lower than its 5-year historical median
Price to Sales (P/S)
1.10
Lower than its 5-year historical median
EV/EBITDA
14.24
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
8.38%
Underperforms industry median
Return on Capital Employed (ROCE)
9.39%
Underperforms industry median
Return on Assets (ROA)
6.45%
Operating Profit Margin
3.1%
Net Profit Margin
14.19%
Gross Profit Margin
17.8%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-5.9%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
-30.74%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
-23.03%
Asset Quality
Promoter Holding
57.19%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹166 Cr.
Equity
₹21 Cr.
Face Value
₹10
All Time Low / High
₹5.50 / 144.60
Check Before You Invest
Quality
Somewhat GoodValuation
FairCheck Valuation charts
Price Trend
Weak
Is Alpa Laboratories Ltd a good quality company?
Alpa Laboratories Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Alpa Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Alpa Laboratories Ltd vs industry peers?
Alpa Laboratories Ltd revenue CAGR is 1.64%, compared to the industry median CAGR of 0.00%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Alpa Laboratories Ltd?
Promoters hold 57.19% of the Alpa Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Alpa Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 6% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Alpa Laboratories Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 9.5% | 7% | 4.8% | 4.8% | 9.5% | 15.5% | 11.3% | 13.4% | 14.9% | 8.9% | - |
| Value Creation Index ⓘ | -0.3 | -0.5 | -0.7 | -0.7 | -0.3 | 0.1 | -0.2 | 0.0 | 0.1 | -0.4 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 63.4 | 62.3 | 78 | 86 | 97.6 | 112 | 93 | 109 | 112 | 106 | 111 |
| Sales YoY Gr. | - | -1.8% | 25.2% | 10.2% | 13.5% | 15.1% | -17.2% | 17% | 3.4% | -5.9% | - |
| Adj EPS ⓘ | 3.3 | 2.2 | 1 | 2.3 | 2.6 | 3.7 | 4.2 | 7.7 | 9.1 | 7.1 | 2.1 |
| YoY Gr. | - | -33.1% | -55.9% | 135.7% | 10.8% | 43.8% | 15.2% | 82.3% | 17.5% | -22.3% | - |
| BVPS (₹) ⓘ | 46.8 | 49.1 | 50.4 | 52.4 | 55.9 | 62.6 | 69 | 77 | 86.7 | 93.4 | 93.9 |
| Adj Net Profit ⓘ | 7 | 4.7 | 2.1 | 4.9 | 5.4 | 7.7 | 8.9 | 16.3 | 19.1 | 14.9 | 4 |
| Cash Flow from Ops. ⓘ | -8.1 | -7.3 | -0.7 | 17.7 | -1.5 | 2.2 | 10.2 | 3.7 | 18.4 | 10 | - |
| Debt/CF from Ops. ⓘ | -1.3 | -0.8 | -2.5 | 0 | -0.1 | 2.7 | 0.3 | 1.4 | 0 | 0.2 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.9% | 1.6% | 4.4% | -5.9% | ||||
| Adj EPS ⓘ | 8.7% | 22.5% | 18.5% | -22.3% | ||||
| BVPSⓘ | 8% | 10.8% | 10.7% | 7.7% | ||||
| Share Price | 6% | 1.2% | -7.5% | -35.2% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 7.3 | 4.6 | 2 | 4.5 | 4.7 | 6.2 | 6.5 | 10.6 | 11.1 | 7.8 | 2.2 |
| Op. Profit Mgn % ⓘ | 11.2 | 6.7 | 1.6 | 6.9 | 8.9 | 9.5 | 8.7 | 7.5 | 4.5 | 3.1 | -1 |
| Net Profit Mgn % ⓘ | 11 | 7.5 | 2.7 | 5.7 | 5.5 | 6.9 | 9.6 | 15 | 17 | 14.1 | 4 |
| Debt to Equity ⓘ | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 432 | 356 | 280 | 238 | 222 | 224 | 279 | 241 | 246 | 273 | 331 |
| Cash Conv. Cycle ⓘ | 147 | 148 | 126 | 106 | 82 | 97 | 154 | 141 | 140 | 136 | 250 |
Valuation of Alpa Laboratories - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 63 | 63 | 78 | 86 | 98 | 112 | 93 | 109 | 112 | 106 |
| Operating Expenses ⓘ + | 56 | 59 | 77 | 83 | 90 | 102 | 85 | 101 | 108 | 103 |
| Operating Profit ⓘ | 7 | 4 | 1 | 3 | 8 | 11 | 8 | 8 | 5 | 3 |
| Operating Profit Margin (%) | 11.2% | 6.2% | 1.5% | 3.9% | 7.9% | 9.5% | 8.7% | 7.5% | 4.2% | 3.1% |
| Other Income ⓘ + | 5 | 5 | 5 | 3 | 4 | 11 | 9 | 15 | 23 | 16 |
| Interest ⓘ | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 3 | 3 | 3 | 3 | 1 | 2 | 1 | 2 | 2 | 2 |
| Profit Before Tax ⓘ | 6 | 5 | 3 | 3 | 11 | 20 | 16 | 21 | 26 | 17 |
| Tax ⓘ | 3 | 2 | 2 | 1 | 4 | 5 | 3 | 4 | 6 | 2 |
| Profit After Tax | 3 | 3 | 1 | 2 | 7 | 14 | 13 | 17 | 20 | 15 |
| PAT Margin (%) | 4.0% | 4.5% | 1.3% | 2.2% | 7.4% | 12.6% | 13.5% | 15.4% | 17.3% | 14.2% |
| Adjusted EPS (₹) | 1.2 | 1.3 | 0.5 | 0.9 | 3.4 | 6.7 | 6.0 | 8.0 | 9.3 | 7.1 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 95 | 98 | 98 | 100 | 108 | 122 | 135 | 152 | 172 | 186 | |
| Debt + | 11 | 6 | 1 | 0 | 0 | 4 | 1 | 4 | 0 | 3 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 14 | 13 | 13 | 14 | 25 | 15 | 15 | 12 | 19 | 18 | |
| Others Liabilities ⓘ | 6 | 4 | 8 | 6 | 8 | 14 | 17 | 14 | 32 | 36 | |
| Total Liabilities ⓘ | 125 | 121 | 121 | 120 | 140 | 155 | 167 | 182 | 223 | 242 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 11 | 10 | 8 | 6 | 7 | 9 | 7 | 11 | 21 | 20 | |
| CWIP ⓘ | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | |
| Investments ⓘ | 13 | 31 | 49 | 57 | 51 | 75 | 78 | 98 | 118 | 142 | |
| Inventories | 13 | 14 | 14 | 13 | 17 | 15 | 13 | 14 | 18 | 13 | |
| Trade Receivables | 29 | 26 | 30 | 25 | 35 | 38 | 47 | 41 | 47 | 41 | |
| Cash Equivalents | 37 | 21 | 1 | 6 | 11 | 2 | 9 | 2 | 2 | 3 | |
| Others Assets ⓘ | 22 | 19 | 20 | 13 | 18 | 16 | 14 | 16 | 17 | 23 | |
| Total Assets ⓘ | 125 | 121 | 121 | 120 | 140 | 155 | 167 | 182 | 223 | 242 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 17 | -13 | -1 | 18 | -2 | 10 | 9 | 4 | 18 | 9 |
| Cash Flow From Investing Activity ⓘ + | -2 | -11 | -15 | -11 | 6 | -16 | 2 | -13 | -12 | -11 |
| Cash Flow From Financing Activity ⓘ + | -15 | 9 | -5 | -1 | 0 | 5 | -4 | 3 | -5 | 2 |
| Net Cash Flow ⓘ | 0 | -15 | -20 | 5 | 4 | -0 | 7 | -7 | 1 | 1 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.68 | 2.92 | 1.03 | 1.86 | 6.97 | 12.29 | 9.82 | 11.71 | 12.04 | 8.38 |
| ROCE (%) | 6.59 | 5.47 | 3.26 | 3.09 | 10.42 | 16.81 | 12.19 | 14.31 | 15.73 | 9.39 |
| Asset Turnover Ratio | 0.47 | 0.51 | 0.65 | 0.71 | 0.75 | 0.76 | 0.58 | 0.62 | 0.55 | 0.45 |
| PAT to CFO Conversion(x) | 5.67 | -4.33 | -1 | 9 | -0.29 | 0.71 | 0.69 | 0.24 | 0.9 | 0.6 |
| Working Capital Days | ||||||||||
| Receivable Days | 182.70 | 160.20 | 131.10 | 115.90 | 112.30 | 119.40 | 166.40 | 147.50 | 142.80 | 151.20 |
| Inventory Days | 80.60 | 77.70 | 65 | 56.50 | 54.50 | 52.10 | 55.20 | 44.20 | 50.80 | 53.40 |
| Payable Days | 163.60 | 137 | 98.90 | 96.20 | 117.90 | 103.70 | 99.60 | 72 | 79.20 | 100.30 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Alpa Laboratories Ltd FAQs
The current trading price of Alpa Laboratories on 14-Oct-2026 16:59 is ₹58.27.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 13-Oct-2026 the market cap of Alpa Laboratories stood at ₹121.2 Cr
The latest P/E ratio of Alpa Laboratories as of 13-Oct-2026 is 27.72.
The latest P/B ratio of Alpa Laboratories as of 13-Oct-2026 is 0.61.
The 52-week high of Alpa Laboratories is ₹99.75 and the 52-week low is ₹46.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Alpa Laboratories is ₹111 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Alpa Laboratories Ltd is a average quality company.
The key valuation ratios of Alpa Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Alpa Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
About Alpa Laboratories Ltd
Incorporated as Alpa Laboratories Private Limited on March 18, 1988 under the Companies Act, 1956 and converted to public limited company on September 3, 1998 with the name of Alpa Laboratories Limited. The company has been listed on the Bombay Stock Exchange and the National Stock Exchange since August 6, 2007.
Alpa Laboratories Limited is a WHO-GMP and ISO 9001:2000 certified company located at Pigdamber, about 15 kilometers from the city of Indore in Central India. The company has been manufacturing Pharmaceutical Finished Dosage Forms since 1967. With its focus on quality, the company has earned tremendous faith and confidence of its associates.
The manufacturing facility is less than 20 kilometers from the center of the city of Indore in Central India and is spread over 1.20 acres. The facility has dedicated manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels. The production areas are designed to maximize output quality and quantity with minimal down time.
The facility is WHO-GMP certified and all manufacturing areas are supplied with independent air supply systems for individual department. The independent supply systems are fed with separate air handling units to avoid cross contamination. Pressure gradients are maintained and monitored and the required air quality of class 100, 1000, 10,000 and class 100,000 is maintained.
Business area of the company
The company manufactures a wide range of products under its own brand and for a number of other reputed Indian and multinational companies. The product range includes a wide variety of ethical, generic and over the counter (OTC) drugs in various Finished Dosage Forms for both human and veterinary use.
Products
Capsules: Equipment used for the production of hard-gelatin capsules are automatic filling machine, feeder, sorter, inspection machine and polishing machine. The filled capsules are packed in high speed automatic strip and blister packing machines suitable for various sizes. The company has the ability to produce both powder filled and granule filled capsules.
Creams, Gels & Ointments: The semi-automatic machines perform the entire process of filling, sealing & crimping of the tubes in various tube sizes of Creams, Gels, Ointments, Sterile Ophthalmic Ointments and Sterile intra-mammary infusions.
Ear & Eye Drops: This department houses sophisticated machines such as automatic sealing, capping, labeling, carton forming and wrapping machines.
Injections: The parenteral is produced in a sterile area and fed to the automatic machines for ampule or vial filling, rubber bunging and cap sealing. A similar process is used for dry powder injections.
Tablets: Rapid Mixer Granulator and Fluid Bed Dryer are used to produce the material for compression in various shapes which is carried out at various multi-station, single and double rotary tablet compression machines. There are coating machines for various types of coating of the tablets. A similar process is used for boluses.
You have 44 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
